|
/s/ Dinesh V. Patel
Dinesh V. Patel, Ph.D.
President and Chief Executive Officer |
| | | |
| |
Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.
|
| |
|
Proposal
Number |
| |
Proposal Description
|
| |
Vote Required for Approval
|
| |
Effect of
Abstentions |
| |
Effect of
Broker Non-Votes |
|
| 1 | | | Election of Directors | | | Nominees receiving the most “For” votes; withheld votes will have no effect. | | | Under plurality voting, there are no abstentions. | | | None | |
| 2 | | | Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2021 | | | “For” votes from the holders of a majority of shares present online during the virtual meeting or represented by proxy and entitled to vote on the matter. | | | Against | | | Not applicable(1) | |
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating and
Corporate Governance |
| |||||||||
Bryan Giraudo
|
| | | | X | | | | | | — | | | | | | X* | | |
Sarah Noonberg, M.D., Ph.D.
|
| | | | X | | | | | | — | | | | | | — | | |
Sarah A. O’Dowd(1)
|
| | | | — | | | | | | — | | | | | | X | | |
Dinesh V. Patel, Ph.D.
|
| | | | — | | | | | | — | | | | | | — | | |
Harold E. Selick, Ph.D.
|
| | | | — | | | | | | X* | | | | | | X | | |
William D. Waddill
|
| | | | X* | | | | | | X | | | | | | — | | |
Lewis T. Williams, M.D., Ph.D.
|
| | | | — | | | | | | X | | | | | | — | | |
Total meetings in fiscal 2020
|
| | | | 9 | | | | | | 6 | | | | | | 2 | | |
| | |
Fiscal Year Ended
December 31, |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Audit Fees(1)
|
| | | $ | 405,000 | | | | | $ | 1,185,300 | | |
Audit-Related Fees(2)
|
| | | | — | | | | | | — | | |
Tax Fees(3)
|
| | | | — | | | | | | 12,085 | | |
All Other Fees(4)
|
| | | | — | | | | | | 2,700 | | |
Total Fees
|
| | | $ | 405,000 | | | | | $ | 1,200,085 | | |
Name
|
| |
AUD: USD
|
| |
AUD
|
| |
USD
|
| |||||||||
2020 Average
|
| | | | 1.00:0.70348 | | | | | $ | — | | | | | $ | — | | |
2019 Average
|
| | | | 1.00:0.69696 | | | | | $ | 17,340 | | | | | $ | 12,085 | | |
| | |
Fiscal Year Ended
December 31, 2020 |
| |||
Audit Fees(1)
|
| | | $ | 860,675 | | |
Audit Related Fees(2)
|
| | | | — | | |
Tax Fees(3)
|
| | | | 80,798 | | |
All Other Fees(4)
|
| | | | — | | |
Total Fees
|
| | | $ | 941,473 | | |
Name
|
| |
AUD: USD
|
| |
AUD
|
| |
USD
|
| |||||||||
2020 Average
|
| | | | 1.00:0.70348 | | | | | $ | 114,855 | | | | | $ | 80,798 | | |
Name
|
| |
Age
|
| |
Position
|
|
Dinesh V. Patel, Ph.D.
|
| |
64
|
| | President, Chief Executive Officer and Director | |
David Y. Liu, Ph.D.
|
| |
70
|
| | Chief Scientific Officer and Head of Discovery & Pre-Clinical Development | |
Donald A. Kalkofen
|
| |
57
|
| | Chief Financial Officer | |
Samuel Saks, M.D.
|
| |
66
|
| | Chief Medical Officer | |
Suneel Gupta, Ph.D.
|
| |
63
|
| | Chief Development Officer | |
| | |
Beneficial Ownership(1)
|
| |||||||||
Beneficial Owner
|
| |
Number
of Shares |
| |
Percent
of Total |
| ||||||
5% Stockholders: | | | | | | | | | | | | | |
BlackRock, Inc.(2)
|
| | | | 2,591,711 | | | | | | 5.9% | | |
Biotechnology Value Fund, LP and its affiliated entities(3)
|
| | | | 2,311,108 | | | | | | 5.3% | | |
Consonance Capital Management LP(4)
|
| | | | 2,729,709 | | | | | | 6.2% | | |
Farallon Partners, LLC(5)
|
| | | | 3,925,000 | | | | | | 8.9% | | |
FMR LLC(6)
|
| | | | 6,452,764 | | | | | | 14.7% | | |
Johnson & Johnson Development Corporation(7)
|
| | | | 2,449,183 | | | | | | 5.6% | | |
RTW Investments, LP(8)
|
| | | | 3,650,069 | | | | | | 8.3% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Dinesh V. Patel, Ph.D.(9)
|
| | | | 1,266,123 | | | | | | 2.8% | | |
Suneel Gupta, Ph.D.(10)
|
| | | | 166,071 | | | | | | * | | |
David Y. Liu, Ph.D.(11)
|
| | | | 350,285 | | | | | | * | | |
Harold E. Selick, Ph.D.(12)
|
| | | | 113,020 | | | | | | * | | |
Bryan Giraudo(13)
|
| | | | 65,333 | | | | | | * | | |
Sarah Noonberg, M.D., Ph.D.(14)
|
| | | | 39,600 | | | | | | * | | |
Sarah A. O’Dowd(15)
|
| | | | 7,500 | | | | | | * | | |
William D. Waddill(16)
|
| | | | 72,975 | | | | | | * | | |
Lewis T. Williams, M.D., Ph.D.(17)
|
| | | | 48,000 | | | | | | * | | |
All executive officers and directors as a group (11 persons)(18)
|
| | | | 2,304,668 | | | | | | 5.0% | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($)(1) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total
($) |
| |||||||||||||||||||||
Dinesh V. Patel, Ph.D.
President and Chief Executive Officer |
| | | | 2020 | | | | | | 565,000 | | | | | | — | | | | | | 1,183,155 | | | | | | 473,894 | | | | | | 3,573 | | | | | | 2,225,622 | | |
| | | 2019 | | | | | | 545,000 | | | | | | 230,575 | | | | | | 814,355 | | | | | | 354,250 | | | | | | 4,164 | | | | | | 1,948,344 | | | ||
David Y. Liu, Ph.D.
Chief Scientific Officer and Head of Discovery and Pre-Clinical Development |
| | | | 2020 | | | | | | 441,300 | | | | | | — | | | | | | 352,429 | | | | | | 266,987 | | | | | | 11,133 | | | | | | 1,071,849 | | |
| | | 2019 | | | | | | 428,450 | | | | | | 120,300 | | | | | | 424,881 | | | | | | 218,509 | | | | | | 7,458 | | | | | | 1,199,598 | | | ||
Suneel Gupta, Ph.D.
Chief Development Officer |
| | | | 2020 | | | | | | 420,000 | | | | | | — | | | | | | 427,950 | | | | | | 256,200 | | | | | | 4,120 | | | | | | 1,108,270 | | |
| | | 2019 | | | | | | 377,467 | | | | | | 60,150 | | | | | | 693,789 | | | | | | 196,767 | | | | | | 3,564 | | | | | | 1,331,737 | | |
Name
|
| |
2020 Base
Salary ($) |
| |
Target
Bonus |
| |
Amount of Bonus
Earned ($) |
| |||||||||
Dinesh V. Patel, Ph.D.
|
| | | | 565,000 | | | | | | 55% | | | | | | 473,894 | | |
David Y. Liu, Ph.D.
|
| | | | 441,300 | | | | | | 40% | | | | | | 266,987 | | |
Suneel Gupta, Ph.D.
|
| | | | 420,000 | | | | | | 40% | | | | | | 256,200 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
| | |
Grant
Date |
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Vesting
Commencement Date |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
| ||||||||||||||||||||||||
Dinesh V. Patel, Ph.D.
|
| | | | 10/22/2014(1) | | | | | | 34,087 | | | | | | — | | | | | $ | 1.89 | | | | | | 11/01/2014 | | | | | | 10/21/2024 | | | | | | — | | | | | | — | | |
| | | 04/29/2016(2) | | | | | | 178,742 | | | | | | — | | | | | $ | 4.21 | | | | | | 04/25/2016 | | | | | | 04/28/2026 | | | | | | — | | | | | | — | | | ||
| | | 10/11/2016(2) | | | | | | 320,000 | | | | | | — | | | | | $ | 21.58 | | | | | | 08/10/2016 | | | | | | 10/10/2026 | | | | | | — | | | | | | — | | | ||
| | | 02/28/2018(2)(3) | | | | | | 106,250 | | | | | | 43,750 | | | | | $ | 16.95 | | | | | | 02/28/2018 | | | | | | 02/27/2028 | | | | | | 12,500 | | | | | | 211,875 | | | ||
| | | 08/15/2018(4) | | | | | | 54,700 | | | | | | — | | | | | $ | 8.58 | | | | | | 08/05/2018 | | | | | | 08/14/2028 | | | | | | — | | | | | | — | | | ||
| | | 02/28/2019(3) | | | | | | 79,062 | | | | | | 93,438 | | | | | $ | 8.02 | | | | | | 02/28/2019 | | | | | | 02/27/2029 | | | | | | 21,563 | | | | | | 172,935 | | | ||
| | | 02/28/2020(2) | | | | | | 48,958 | | | | | | 186,042 | | | | | $ | 7.80 | | | | | | 02/28/2020 | | | | | | 02/27/2030 | | | | | | — | | | | | | — | | | ||
David Y. Liu, Ph.D.
|
| | | | 09/26/2013(1) | | | | | | 23,767 | | | | | | — | | | | | $ | 0.87 | | | | | | 06/01/2013 | | | | | | 09/25/2023 | | | | | | — | | | | | | — | | |
| | | 10/22/2014(1) | | | | | | 9,726 | | | | | | — | | | | | $ | 1.89 | | | | | | 11/01/2014 | | | | | | 10/21/2024 | | | | | | — | | | | | | — | | | ||
| | | 03/26/2015(2) | | | | | | 5,999 | | | | | | — | | | | | $ | 1.89 | | | | | | 03/26/2015 | | | | | | 03/25/2025 | | | | | | — | | | | | | — | | | ||
| | | 10/28/2015(2) | | | | | | 35,656 | | | | | | — | | | | | $ | 1.16 | | | | | | 09/01/2015 | | | | | | 10/27/2025 | | | | | | — | | | | | | — | | | ||
| | | 04/29/2016(2) | | | | | | 35,331 | | | | | | — | | | | | $ | 4.21 | | | | | | 04/25/2016 | | | | | | 04/28/2026 | | | | | | — | | | | | | — | | | ||
| | | 10/11/2016(2) | | | | | | 65,000 | | | | | | — | | | | | $ | 21.58 | | | | | | 08/10/2016 | | | | | | 10/10/2026 | | | | | | — | | | | | | — | | | ||
| | | 02/28/2018(2)(3) | | | | | | 40,020 | | | | | | 16,480 | | | | | $ | 16.95 | | | | | | 02/28/2018 | | | | | | 02/27/2028 | | | | | | 4,750 | | | | | | 80,512 | | | ||
| | | 08/15/2018(4) | | | | | | 17,200 | | | | | | — | | | | | $ | 8.58 | | | | | | 08/05/2018 | | | | | | 08/14/2028 | | | | | | — | | | | | | — | | | ||
| | | 02/28/2019(2)(3) | | | | | | 41,250 | | | | | | 48,750 | | | | | $ | 8.02 | | | | | | 02/28/2019 | | | | | | 02/27/2029 | | | | | | 11,250 | | | | | | 90,225 | | | ||
| | | 02/28/2020(2) | | | | | | 14,583 | | | | | | 55,417 | | | | | $ | 7.80 | | | | | | 02/28/2020 | | | | | | 02/27/2030 | | | | | | — | | | | | | — | | | ||
Suneel Gupta, Ph.D.
|
| | | | 01/15/2019(1) | | | | | | 52,708 | | | | | | 57,292 | | | | | $ | 7.38 | | | | | | 01/07/2019 | | | | | | 01/14/2029 | | | | | | — | | | | | | — | | |
| | | 02/28/2019(2)(3) | | | | | | 20,625 | | | | | | 24,375 | | | | | $ | 8.02 | | | | | | 02/28/2019 | | | | | | 02/27/2029 | | | | | | 5,625 | | | | | | 45,113 | | | ||
| | | 02/28/2020(2) | | | | | | 17,708 | | | | | | 67,292 | | | | | $ | 7.80 | | | | | | 02/28/2020 | | | | | | 02/27/2030 | | | | | | — | | | | | | — | | |
| | |
Stock Options
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of
Shares Acquired Upon Exercise (#) |
| |
Value
Realized Upon Exercise ($)(1) |
| |
Number of
Shares Acquired Upon Vesting (#) |
| |
Value
Realized Upon Vesting ($)(2) |
| ||||||||||||
Dinesh V. Patel, Ph.D.
|
| | | | 28,344 | | | | | | 138,859 | | | | | | 40,787 | | | | | | 331,785 | | |
David Y. Liu, Ph.D.
|
| | | | — | | | | | | — | | | | | | 14,725 | | | | | | 119,374 | | |
Suneel Gupta, Ph.D.
|
| | | | — | | | | | | — | | | | | | 1,875 | | | | | | 14,850 | | |
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Option
Awards ($)(2)(3) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||
Former Non-Employee Directors | | | | | | | | | | | | | | | | | | | | | | | | | |
Chaitan Khosla, Ph.D.(1)
|
| | | | 33,750 | | | | | | 154,319 | | | | | | — | | | | | | 188,069 | | |
Current Non-Employee Directors | | | | | | | | | | | | | | | | | | | | | | | | | |
Bryan Giraudo
|
| | | | 61,250 | | | | | | 154,319 | | | | | | — | | | | | | 215,569 | | |
Sarah Noonberg, M.D., Ph.D.
|
| | | | 50,625 | | | | | | 154,319 | | | | | | — | | | | | | 204,944 | | |
Sarah A. O’Dowd
|
| | | | 16,685 | | | | | | 344,553 | | | | | | — | | | | | | 361,238 | | |
Harold E. Selick, Ph.D.
|
| | | | 97,812 | | | | | | 154,319 | | | | | | — | | | | | | 252,131 | | |
William D. Waddill
|
| | | | 69,375 | | | | | | 154,319 | | | | | | — | | | | | | 223,694 | | |
Lewis T. Williams, M.D., Ph.D.
|
| | | | 48,125 | | | | | | 154,319 | | | | | | — | | | | | | 202,444 | | |
Name
|
| |
Aggregate Number of
Option Awards Outstanding as of December 31, 2020 |
| |||
Bryan Giraudo
|
| | | | 63,000 | | |
Chaitan Khosla, Ph.D.
|
| | | | — | | |
Sarah Noonberg, M.D., Ph.D.
|
| | | | 63,000 | | |
Sarah A. O’Dowd
|
| | | | 30,000 | | |
Harold E. Selick, Ph.D.
|
| | | | 112,710 | | |
William D. Waddill
|
| | | | 87,975 | | |
Lewis T. Williams, M.D. Ph.D.
|
| | | | 63,000 | | |
Plan Category(1)
|
| |
Number of securities
to be issued upon exercise of outstanding options, warrants and rights (a) |
| |
Weighted
average exercise price of outstanding options, warrants and rights(6) (b) |
| |
Number of securities
remaining available for issuance under equity compensation plans (excluding securities reflected in column (a)) (c) |
| |||||||||
Equity compensation plans approved by securities holders:
|
| | | | | | | | | | | | | | | | | | |
2007 Stock Option and Incentive Plan
|
| | | | 512,178(3) | | | | | $ | 3.43 | | | | | | — | | |
2016 Equity Incentive Plan
|
| | | | 3,724,487(4) | | | | | $ | 12.91 | | | | | | 538,374(7) | | |
2016 Employee Stock Purchase Plan
|
| | | | — | | | | | | — | | | | | | 757,647(8) | | |
Equity compensation plans not approved by securities holders:
|
| | | | | | | | | | | | | | | | | | |
2018 Inducement Plan(2)
|
| | | | 656,000(5) | | | | | $ | 12.96 | | | | | | 574,375 | | |
Total
|
| | | | 4,892,665 | | | | | $ | 11.28 | | | | | | 1,870,395 | | |
|
/s/ Dinesh V. Patel
Dinesh V. Patel, Ph.D.
President and Chief Executive Officer |
| | | |